Information, not a decision

Glioblastoma: tumour board sheet

Dated public registry data. It contains no treatment recommendation. 12 Nov 2026

Open trials (460)

NCT07480941	Phase 1	Dual-Targeting CAR-NK Cell Therapy for Recurrent/Progressive Glioblastoma and High-Grade Glioma	Recruiting
NCT07551336	Phase 1	Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma	Recruiting
NCT06914128	Phase 1/2	A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors	Recruiting
NCT06910306	No phase	Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma	Recruiting
NCT07326566	Phase 2	Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII	Recruiting
NCT07927491	Phase 1	Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)	Not yet recruiting
NCT07929909	Phase 1	A Phase I Clinical Study of YN003 in the Treatment of Glioma	Recruiting
NCT07389278	Phase 1/2	Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)	Not yet recruiting
NCT05432804	Phase 1/2	Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment	Recruiting
NCT07524140	Phase 1	A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors	Recruiting
NCT07356973	Phase 2	Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma	Recruiting
NCT07195591	Phase 3	Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care	Recruiting

448 more in the doctor's list on the site.

No phase 3 trial in this list ended in the last 90 days.

Links only: read the guideline itself.

Made from the public data of Frontlight Research. Source: ClinicalTrials.gov. 12 Nov 2026

https://frontlightresearch.com/en/doctor/glioblastoma/tumor-board